Therapeutic options for metastatic breast cancer Journal Article
| Authors: | Morris, P. G.; Mcarthur, H. L.; Hudis, C. A. |
| Article Title: | Therapeutic options for metastatic breast cancer |
| Abstract: | Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment. © 2009 Informa UK Ltd. All rights reserved. |
| Keywords: | cancer surgery; survival rate; overall survival; clinical trial; constipation; fatigue; neutropenia; review; bevacizumab; cisplatin; doxorubicin; fluorouracil; placebo; cancer combination chemotherapy; diarrhea; drug dose comparison; drug dose reduction; hypertension; monotherapy; side effect; unspecified side effect; antineoplastic agents; clinical trials as topic; pathophysiology; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; chemotherapy; drug megadose; neurotoxicity; animals; carboplatin; metastasis; multiple cycle treatment; sensory neuropathy; breast cancer; bone marrow suppression; bleeding; blood toxicity; mucosa inflammation; nausea; stomatitis; thrombocytopenia; vomiting; antineoplastic combined chemotherapy protocols; myalgia; ovariectomy; peripheral neuropathy; aromatase inhibitor; estrogen; estrogen therapy; cyclophosphamide; breast neoplasms; cancer therapy; bone density; docetaxel; exemestane; arthralgia; asthenia; drug dose escalation; drug receptor binding; injection site reaction; loading drug dose; rash; drug delivery systems; wound healing; antibodies, monoclonal; dosage schedule comparison; cardiotoxicity; thrombosis; erythema; tamoxifen; epirubicin; injection site pain; hyperbilirubinemia; letrozole; gonadorelin agonist; drug half life; anthracycline derivative; estrogen receptor; trastuzumab; anastrozole; navelbine; hand foot syndrome; alopecia; proteinuria; lapatinib; targeted agents; urticaria; fulvestrant; ixabepilone; fluid retention; endocrine therapy; metastatic disease; aromatase; medroxyprogesterone acetate; toremifene; phlebitis; vasomotor disorder; vasomotor symptom |
| Journal Title: | Expert Opinion on Pharmacotherapy |
| Volume: | 10 |
| Issue: | 6 |
| ISSN: | 1465-6566 |
| Publisher: | Informa Healthcare |
| Date Published: | 2009-04-01 |
| Start Page: | 967 |
| End Page: | 981 |
| Language: | English |
| DOI: | 10.1517/14656560902834961 |
| PUBMED: | 19351274 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 30 November 2010" - "CODEN: EOPHF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work